Xuemei Zeng, Yijun Chen, Anuradha Sehrawat, Jihui Lee, Tara K Lafferty, Julia Kofler, Sarah B Berman, Robert A Sweet, Dana L Tudorascu, William E Klunk, Milos D Ikonomovic, Anna Pfister, Henrik Zetterberg, Beth E Snitz, Anne D Cohen, Victor L Villemagne, Tharick A Pascoal, M Llyas Kamboh, Oscar I Lopez, Kaj Blennow, Thomas K Karikari
Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely available and cost-effective modalities for diagnosis and prognosis. Recently, the blood-based AD biomarker field has seen significant progress driven by technological advances, mainly improved analytical sensitivity and precision of the assays and measurement platforms. Several blood-based biomarkers have shown high potential for accurately detecting AD pathophysiology...
May 15, 2024: Molecular Neurodegeneration